WHO Raises Warning Over Acute Lack of Obesity Medications
Under a tenth of patients eligible to benefit from weight-loss injections such as Wegovy are able to get them, warns the global health agency as it issues its initial guidance on the therapies.
Considering in excess of 1,000,000,000 people worldwide currently obese, it is urging more widespread and fairer availability to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"Our latest guidance acknowledges that obesity is a chronic disease that can be addressed with thorough and ongoing care," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are significant barriers to broad availability to the jabs that can help people shift significant body mass, explains the organization.
Weight-Loss Drug Shortage
Despite the present most favorable case, the production of such drugs would only suffice for approximately 100 million people – less than 10% of eligible patients, according to the health organization.
The recommendation encourages nations and manufacturers to widen availability, via approaches such as voluntary licensing.
The intellectual property rights on semaglutide – the core ingredient of a leading brand – is scheduled to end in multiple nations in 2026.
The Way Weight-Loss Injections Function
These medications mimick a natural hormone to delay gastric emptying, reduce hunger and increase satiety so users consume fewer calories.
Patients usually begin shedding pounds in the initial weeks of commencing the weekly injections.
Evidence indicates people may regain a significant portion after a year of halting the treatment, when their usual hunger come back.
Being carrying excess weight elevates your risk for experiencing diseases, like diabetes, heart disease, brain attack, and some malignancies.
Excess weight impacts people in every country and was linked to 3.7 million deaths worldwide in 2024, per the WHO.
